

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Rochus JONAS et al. Serial No.: 10/088,023 Group Art Unit: 1614 Filed: July 29, 2002 Examiner: UNASSIGNED For: USE OF THIENOPYRIMIDINES INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98 **Assistant Commissioner for Patents** Washington, D. C. 20231 Sir: This Information Disclosure Statement is made in accordance with 37 C.F.R. §§ 1.56, 1.97 and 1.98 as follows: **TIMING AND FEES** \boxtimes Under 37 C.F.R. § 1.97(b), no fee or statement is required: Within three months of the filing date of a national application other than a CPA under § 1.53(d); OR Within three months of the date of entry of the national stage of an international; Before the mailing of a first Office Action on the merits after filing a RCE; or \boxtimes

Before the mailing of a first Office Action on the merits after fining a RCE, of

Before the mailing of a first Office Action on the merits.

No fee or statement is required.

Under 37 C.F.R. § 1.97(c):

After the periods specified in 37 C.F.R. § 1.97(b), but before the mailing date of either:

A Final Action or under 37 C.F.R. 1.113; OR

A Notice of Allowance under 37 C.F.R. § 1.311; and is accompanied by: (check one)

The statement as specified in 37 C.F.R. § 1.97(e) set out below; OR

A check covering the fee of \$180.00 under 37 C.F.R. § 1.17(p).

•						
·	Under 37 C.	.R. § 1.97(d):				
	After the ma	After the mailing date of either:				
		a Final Action or under 37 C.F.R. § 1.113; OR				
		a Notice of Allowance under 37 C.F.R. § 1.311;				
	BUT is filed	on or before payment of the Issue Fee; AND is accomp	panied by:			
		The statement as specified in 37 C.F.R. § 1.97(e) as sthe Petition fee of \$130.00 set out in 37 C.F.R. § 1.1	-			
	Statements 1	<u>Under 37 C.F.R. 1.97(e)</u>				
ć		Each item of information contained in this Infor Statement was cited in a communication from a foreign counterpart foreign application not more than three filing date of this Information Disclosure Statement;	gn patent office in a months prior to the			
		No item of information contained in this Information Statement was cited in a communication from a foreign counterpart foreign application, and to the knowledge Attorney after making reasonable inquiry, not its contained in this Information Disclosure Statement prior individual designated in 37 C.F.R. § 1.56(c) more prior to the filing date of the Information Disclosure	gn patent office in a of the undersigned em of information was known to any the than three months			
\boxtimes	Cited Mater	<u>ials</u>				
		es of materials listed but not attached were cited in parer; see 37 C.F.R. § 1.98(d).	nt application Serial			
	Repo copi	des of materials listed but not attached were cited in an International des of references was confirmed by the PCT International in the Notice of Acceptance mailed November 15, 200	Search Report and Division of the U.S.			
	Non-English	Language References				
		reference(s): in the English-language is (are) indic bases to correspond to the reference(s): , respecti	-			
	(An)	English-language translation(s) of the references:	is (are) provided.			
	A co	mmercial English-language abstract of reference(s)	is (are) provided.			
		English-language search report or an equivalent paper from the cited reference of the cited reference of the cited reference.				
	A fo	reign-language search report from a foreign patent offic	e is provided.			

	Additional Information
	[NONE]
Payme	nt of Fees Due (If Any):
	A check for \$ covering the fee identified above is attached.
	Please charge to Deposit Account No. 13-3402 \$ for the fee identified above.
Accoun	The Commissioner is hereby authorized to charge or credit any overpayment to Deposit nt #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,

Richard J. Traverso, Reg. No. 30,595 Attorney/Agent for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
Arlington Courthouse Plaza 1
2200 Clarendon Blvd. Suite 1400
Arlington, Virginia 22201
Telephone: (703) 243-6333
Facsimile: (703) 243-6410

Attorney Docket No.: MERCK-2397

Date: December 16, 2002

RJT:jk

ease type a plus sign (+) inside this box + +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO Complete if Known Application Number 10/088,023 INFORMATION DISCLOSURE Filing Date July 29, 2002 STATEMENT BY APPLICANT First Named Inventor Rochus JONAS et al Group Art Unit 1614 (use as many sheets as necessary) Examiner Name **UNASSIGNED** Sheet of Attorney Docket Number **MERCK-2397**

				U.S. PATENT DOCUM	MENTS		
-	0	U.S. Patent Document Kind Code ² (if known) 5,948,911		Name of Patentee or Applicant of Cited Document Ono Pharmaceutical Co.	Date of Publication of Cited Document MM-DD-YYYY 08/28/1996	Pages, Columns, Lines, Where Relevar Passages or Relevant Figures Appear	
Examiner Initials *	Cite No. ¹						
	1						
							
		-					
							
							
	ļ						

				FOREIG	N PATENT DOCU	MENTS		
Examiner Initials*	Cite No.1	For Office ³	eign Patent Doc	 Kind Code⁵	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant	_
	2	EP	0 728 759 A	(if known)	Pamukcu Rifat et al	09/07/1999	Figures Appear	T ₆
								
		1		1				

Signature Considered		
----------------------	--	--

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark hee if English language Translation is attached.